,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-10-21 23:50:00,"BostonScientific ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 13 cents in the third quarter of 2014, 30% ahead of the year-ago adjusted number.",0.8642403483390808,0.06730283796787262,0.06845677644014359,positive,0.7969375252723694
1,2014-10-21 23:50:00,"However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 20 cents, 17.6% ahead of the year-ago adjusted number.",0.514573872089386,0.38711223006248474,0.09831397980451584,positive,0.12746164202690125
2,2014-10-21 23:50:00,This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate.,0.41664084792137146,0.01582079380750656,0.5675383806228638,neutral,0.4008200466632843
3,2014-10-21 23:50:00,"Without these adjustments, the company reported net income of $43 million or EPS of 3 cents in the quarter, a huge increase from the year-ago net loss of $5 million or breakeven earnings a share, respectively.",0.9456466436386108,0.029627325013279915,0.02472607046365738,positive,0.9160193204879761
4,2014-10-21 23:50:00,"Revenues in the third quarter registered a 6.4% increase year over year (7% growth at constant exchange rate or CER, excluding divested business) to $1.846 billion.",0.9588243961334229,0.018400492146611214,0.02277510054409504,positive,0.9404239058494568
5,2014-10-21 23:50:00,The figure exceeded the Zacks Consensus Estimate of $1.822 billion.,0.8053467869758606,0.029594765976071358,0.1650584638118744,positive,0.7757520079612732
6,2014-10-21 23:50:00,"Earlier, the company had provided third quarter revenue expectation in the range of $1.79-$1.84 billion.",0.07716822624206543,0.017521606758236885,0.9053102135658264,neutral,0.059646621346473694
7,2014-10-21 23:50:00,"Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.",0.020252270624041557,0.006100116763263941,0.9736475944519043,neutral,0.014152154326438904
8,2014-10-21 23:50:00,"The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions.",0.028852129355072975,0.00474511319771409,0.9664027690887451,neutral,0.024107016623020172
9,2014-10-21 23:50:00,"Sales in these sub-segments were $508 million (up 8% year over year at CER) and $215 million (up 9%), respectively, during the quarter.",0.9285102486610413,0.018101565539836884,0.053388215601444244,positive,0.9104086756706238
10,2014-10-21 23:50:00,"Global sales of coronary stent system (within Interventional Cardiology) were $298 million, up 7.6%.",0.9498112797737122,0.019138464704155922,0.03105027973651886,positive,0.930672824382782
11,2014-10-21 23:50:00,The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million.,0.842388391494751,0.12372501194477081,0.03388660028576851,positive,0.7186633944511414
12,2014-10-21 23:50:00,"The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.",0.10381655395030975,0.00600202102214098,0.8901814818382263,neutral,0.09781453013420105
13,2014-10-21 23:50:00,CRM reflected sales improvement of 4% to $480 million at CER.,0.9569048881530762,0.026294119656085968,0.01680094562470913,positive,0.9306107759475708
14,2014-10-21 23:50:00,"Worldwide sales from pacemakers (within CRM) dropped 1.5% to $132 million, while defibrillators increased 5.5% to $348 million.",0.02090342529118061,0.96998131275177,0.009115233086049557,negative,-0.9490779042243958
15,2014-10-21 23:50:00,Electrophysiology sales surged a massive 57% year over year at CER to $54 million.,0.9550369381904602,0.020201046019792557,0.024761999025940895,positive,0.9348359107971191
16,2014-10-21 23:50:00,"Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments.",0.9060390591621399,0.012852884829044342,0.08110802620649338,positive,0.8931861519813538
17,2014-10-21 23:50:00,"The improved performance in these core segments in the reported quarter, proved beyond doubt that the measures undertaken are working effectively to counter the ongoing challenges.",0.9460527300834656,0.016139205545186996,0.037808019667863846,positive,0.9299135208129883
18,2014-10-21 23:50:00,"Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $336 million (up 7% at CER), $137 million (up 5%) and $115 million (no growth), respectively.",0.864272952079773,0.019553162157535553,0.11617397516965866,positive,0.8447197675704956
19,2014-10-21 23:50:00,Gross margin was down 40 basis points (bps) year over year to 70.2%.,0.017189932987093925,0.9718817472457886,0.01092821266502142,negative,-0.9546918272972107
20,2014-10-21 23:50:00,Adjusted operating margin contracted 112 bps to 17.4% in the quarter.,0.11655930429697037,0.8728846311569214,0.010556088760495186,negative,-0.7563253045082092
21,2014-10-21 23:50:00,"During the reported quarter, selling, general and administrative expenses increased 12.6% to $741 million while research and development expenses dropped 2.3% to $212 million.",0.5932008028030396,0.3676939904689789,0.039105188101530075,positive,0.22550681233406067
22,2014-10-21 23:50:00,Royalty expense also plunged 25% to $21 million.,0.04373694583773613,0.9425167441368103,0.013746336102485657,negative,-0.8987798094749451
23,2014-10-21 23:50:00,"Boston Scientific exited the third quarter with cash and cash equivalents of $246 million, up from $217 million at the end of fiscal 2013, and had long-term debt of $4.25 billion.",0.9393951296806335,0.017037425190210342,0.04356735199689865,positive,0.9223576784133911
24,2014-10-21 23:50:00,The company generated operating cash flow of $346 million in the quarter.,0.0791582465171814,0.012979399412870407,0.9078623056411743,neutral,0.06617884337902069
25,2014-10-21 23:50:00,Boston Scientific increased the lower end of its 2014 adjusted EPS guidance to the range of 81-83 cents from the earlier guided 79-83 cents (considering all one-time items including amortized expense).,0.9151350259780884,0.018587583675980568,0.06627737730741501,positive,0.8965474367141724
26,2014-10-21 23:50:00,"Estimated revenues, on the other hand, have been narrowed to $7.370-$7.420 billion (growth of 3% to 4% on an operational basis) from the earlier guidance of $7.325-$7.425 billion (growth of 3% to 5%).",0.026933051645755768,0.9588148593902588,0.01425214298069477,negative,-0.9318817853927612
27,2014-10-21 23:50:00,The current Zacks Consensus Estimate for EPS of 82 cents and revenues of $7.394 billion coincide with the company's outlook.,0.05713282898068428,0.006610042881220579,0.9362571239471436,neutral,0.050522785633802414
28,2014-10-21 23:50:00,"For the fourth quarter of 2014, adjusted earnings are expected to remain in the band of 20-22 cents per share while the company predicts revenues within $1.875âˆ’$1.925 million.",0.22316259145736694,0.02456079237163067,0.752276599407196,neutral,0.19860179722309113
29,2014-10-21 23:50:00,"The Zacks Consensus Estimate for EPS stands at 21 cents, while that for revenues is $1.919 billion.",0.016673628240823746,0.04963669925928116,0.9336897134780884,neutral,-0.03296307101845741
30,2014-10-21 23:50:00,"Despite challenging economic conditions, a competitive environment, pressure on margins and currency headwinds, Boston Scientific posted a decent third-quarter 2014, in line with our estimates on both the earnings and revenue front.",0.9435874819755554,0.031884536147117615,0.024528024718165398,positive,0.9117029309272766
31,2014-10-21 23:50:00,The companyhas managed to post an impressive performance with balanced growth across all its segments.,0.9503828883171082,0.017067058011889458,0.03255004063248634,positive,0.9333158135414124
32,2014-10-21 23:50:00,"Moreover, the improved guidance for 2014 also helps us to rely on the sustainability of this growth performance.",0.9306030869483948,0.01592574454843998,0.05347123742103577,positive,0.9146773219108582
33,2014-10-21 23:50:00,We are also optimistic about the recent update on the company's growth objectives.,0.7547824382781982,0.013314914889633656,0.23190268874168396,positive,0.7414675354957581
34,2014-10-21 23:50:00,"Boston Scientific is focusing on strategic initiatives like portfolio expansion, restructuring initiatives which include the 2014 restructuring plan, focus on emerging markets and share repurchases.",0.24772001802921295,0.0066911885514855385,0.7455887794494629,neutral,0.24102883040905
35,2014-10-21 23:50:00,"Moreover, Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line.",0.8452548384666443,0.011048102751374245,0.14369715750217438,positive,0.834206759929657
36,2014-10-21 23:50:00,"We are, at the same time, encouraged by the focus on emerging markets, especially India and China.",0.6684192419052124,0.011948986910283566,0.3196317255496979,positive,0.6564702391624451
37,2014-10-21 23:50:00,We take a note that recently the company closed the acquisition of the Interventional Division of Bayer AG which it expects to boost growth in peripheral atherectomy and thrombectomy categories.,0.929667592048645,0.012413755059242249,0.05791870877146721,positive,0.917253851890564
38,2014-10-21 23:50:00,"Currently, Boston Scientific retains a Zacks Rank #3 (Hold).",0.026575138792395592,0.010301409289240837,0.9631235003471375,neutral,0.016273729503154755
39,2014-10-21 23:50:00,"Some of the better-placed Medical Product stocks are Abaxis, Inc. ( ABAX ), Alere Inc. ( ALR ) and ICU Medical, Inc. ( ICUI ), all carrying a Zacks Rank #2 (Buy).",0.7659440636634827,0.034443438053131104,0.19961246848106384,positive,0.7315006256103516
40,2014-10-21 23:50:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
41,2014-10-21 23:50:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
42,2014-10-21 23:50:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
43,2014-10-21 23:50:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
